Introduction {#Sec1}
============

Influenza A viruses (single-stranded, negative-sense RNA viruses) are a major determinant of acute respiratory infections and an important cause of death worldwide. They are responsible not only for the recurrent epidemics but also for occasional pandemics due to major changes in antigenicity (as a result of mixing the segmented genome of two parent viruses of different origin, also called "antigenic shift") leading up to half a million of people to death every year \[[@CR1]\]. During the 2009 influenza pandemic, due to the emergence of a new influenza A virus subtype H1N1 \[A(H1N1)pdm09\] \[[@CR2]\], Greece experienced two waves of transmission, where 294 patients received intensive care treatment and 149 patients died \[[@CR3], [@CR4]\]. In post-pandemic season 2010--11, pandemic influenza A(H1N1)pdm09 was by far the most commonly detected virus (97,5% in Greece) resulting to 368 admissions to intensive-care units (ICUs) and 180 deaths in Greece \[[@CR5], [@CR6]\].

Although seasonal influenza virus infection is in vast majority mild and limited in the upper respiratory tract, in a small subset of patients it can cause primary viral pneumonia as a complication and a minority may even evolve into acute respiratory distress syndrome (ARDS) and lead to death \[[@CR7], [@CR8]\]. Disease severity is usually associated with a plethora of host factors such as age (\> 65), pregnancy, obesity, and underlying medical conditions including pulmonary, cardiovascular, renal, or hepatic disease, chronic metabolic disorder (including diabetes mellitus) or immunosuppression \[[@CR9]\]. Moreover, the risk of a secondary bacterial pneumonia commonly caused by *Streptococcus pneumoniae, Staphylococcus aureus*, and *Haemophilus influenzae* is a key complication of influenza virus infection particularly in the elderly \[[@CR10]\]. Notably, in the recent pandemic of 2009, 65% (80% of the respiratory and cardiovascular deaths) of influenza A(H1N1)pdm09 deaths worldwide were in individuals aged 18--64 years \[[@CR11]\], whereas people over 65 years of age tended to have milder symptoms probably due to cross-protective immunity induced by previous H1N1 influenza infection or vaccination \[[@CR12]\].

To understand the pathogenicity of influenza viruses, numerous parameters implicating both the host and the virus must be considered. These determinants are mainly the essential virulence of the virus, the acquired host immunity and the inheritable host factors whose importance in severity determination is only recently being underscored and granted major attention, especially after the emergence of the 2009 pandemic \[[@CR13], [@CR14]\]. The keystone that triggered studies on innate host factors was the observation of increased death rate among young adults and children without known risk factor mentioned before \[[@CR15]\]. Using the genealogic database of families of Utah between 1904 and 2004, Albright et al. documented a significant association of influenza-associated death risk within families underlying the inherited predisposition of susceptibility to severe influenza infection \[[@CR16]\]. In view of the contradictory results obtained by a second epidemiological study in Iceland with substantially smaller sample size \[[@CR17]\], further investigation is needed to reveal the role of host genetic factors in the severity of influenza infections.

Recent technological advances have promoted the identification of host genetic factors involved in the life cycle of several viruses, such as HIV-1, HCV, Dengue virus, West Nile virus, CMV, RSV and HPV \[[@CR18]--[@CR20]\]. Similarly, a number of recent studies, using different strategies (genome-wide screens, proteomics or transcriptomics approaches, etc.) both in humans and in animal models, aim to reproduce and validate candidate genes retrieved mainly from genetic association studies that predispose to severe influenza \[[@CR21]--[@CR23]\]. Genetic polymorphisms vary among different individuals in each population and usually involve the substitution of a single nucleotide (single nucleotide polymorphism, SNP). Although the estimated SNP frequency within the human genome was about one SNP per 1000 base pairs, which corresponds to 3 million SNPs in total \[[@CR24], [@CR25]\], the international HapMap project reported about 10 million SNPs with a minor allele frequency (MAF) of at least 5% \[[@CR26]\]. The different SNPs may affect in diverse ways the produced protein, and thus the phenotype, depending on their location: within a coding or non-coding sequence.

Several potential genetic polymorphisms predisposing for influenza severity have been recently described, including complement regulatory protein CD55; complement component 1, q subcomponent binding protein (C1QBP) gene; Fc fragment of immunoglobulin G, low-affinity IIA, receptor (FCGR2A) gene; interferon-inducible transmembrane protein 3 (IFITM3); tumor necrosis factor (TNF) gene; RPA interacting protein (RPAIN) gene; ST3 beta-galactosidase alpha − 2,3-sialyltransferase 1 (ST3GAL1) gene; lymphotoxin-alpha (LTA) gene and killer-cell immunoglobulin-like receptor (KIR) gene \[[@CR22], [@CR27]--[@CR31]\].

CD55, or complement decay-accelerating factor (DAF), encodes a glycoprotein involved in the regulation of the complement cascade and participates in host cells protection from damage of pathogenic microorganisms \[[@CR32]\]. Two further SNPs mapped in C1QBP (rs3786054) and FCGR2A (rs1801274) genes have been reported to associate with severe A influenza cases (ORs 3.13 and 2.68, respectively; *P* \< 0.0001) in Mexico in 2009 \[[@CR22]\]. C1QBP gene encodes a protein that binds to the globular heads of C1q molecules and can activate the classical pathway of complement \[[@CR33]\], while FCGR2A encodes a member of a family of immunoglobulin Fc receptor genes found on the surface of phagocytic cells such as macrophages and neutrophils, and is involved in the process of phagocytosis and clearing of immune complexes \[[@CR34]\].

In view of contradictory results observed in the current literature regarding the importance of host genetic polymorphisms in influenza severity, as well as their insufficient study, prompted us to investigate the association between SNPs of CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 and severity of pandemic A(H1N1)pdm09 influenza in a European population. The polymorphisms selected are innate-immunity-related gene SNPs that were by previous genome-wide association studies (GWAS) initially proposed to be associated with severe A(H1N1)pdm09 infection, and their clinical significance needs to be validated. Thus, the aim of the present study has been to identify reliable host genetic risk factors associated with influenza A(H1N1)pdm09 outcome.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

During the post-pandemic influenza period 2010--11, pharyngeal swabs or aspirate samples were sent to the National Influenza Center for Northern Greece for laboratory confirmation of influenza A(H1N1)pdm09 by one-step RT-PCR, according to a protocol developed by the Centre for Disease Control and Prevention \[[@CR35]\]. In the present study, patients with confirmed A(H1N1)pdm09 influenza infection were recruited and classified as mild (control) or severe cases according to their clinical characteristics, such as, admission to the intensive care unit, requirement for oxygen supplementation and especially the presence or not of pneumonia according to the guidelines of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) \[[@CR36]\] at baseline, as reported by individual clinicians. The samples were collected between January and February of the post-pandemic influenza period 2010--11 from 23 state hospitals and two Social Insurance Institutes (IKAs) from northern Greece. Moreover, to achieve uniformity in our study groups the following exclusion criteria were set: patients older than 60 years, other than Greek, or preexisting comorbidities in accordance to WHO risk factors. The demographic and clinical features of the study participants are shown in Table [1](#Tab1){ref-type="table"}. The ethical approval of this study has been provided by the "Bioethics Committee of the Medical School of the Aristotle University of Thessaloniki" (protocol approval number 432).

Table 1Demographic and clinical characteristics of patients with mild or severe disease associated with influenza A(H1N1)pdm09 infectionDisease classificationCharacteristicTotalMildSevere*P* valueSubjects, *n*1105159Mean age, years, ± SD35.62 ± 18.6534.37 ± 18.5636.7 ± 18.830.123Mean age of fatal cases, years, ± SD48.21 ± 7.8852.67 ± 8.7447.37 ± 7.730.997Gender (%) Male6631 (60.8)35 (59.3)1.000 Female4420 (39.2)24 (40.7)Vaccination (%) Yes7 (6.4)5 (9.8)2 (3.4)0.246 No103 (93.6)46 (90.2)57 (96.6)Fatality (%) Yes19 (17.3)3 (5.9)16 (27.1)0.005\* No91 (82.7)48 (94.1)43 (72.9)\**P* \< 0.05

Genotyping {#Sec4}
----------

Genomic DNA was extracted from patient samples using pharyngeal swabs or aspirate samples by the use of the QIAamp DNA Mini Kit (Qiagen, Germany). In brief, 1 ml of the sample was centrifuged at maximum speed (14,000 rpm) for 15 min and 200 µl of the precipitate was further processed following the manufacturer's instructions. The concentration and the purity of the isolated DNAs were evaluated spectrophotometrically by the absorbance ratios at A260/A280 and A260/A230, respectively, using a Nanodrop ND-1000 (Thermo Fisher Scientific, Wilmington, USA). Extracted DNA samples were stored at − 20 °C until processing for genotyping analysis.

Allelic discrimination of three polymorphisms, CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 was performed by real-time PCR using TaqMan technology on Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems Inc., CA, USA). Primers and probes were obtained from Applied Biosystems and available information to the SNPs is presented in Table [2](#Tab2){ref-type="table"}. Genotyping of each sample was performed using the TaqMan Genotyping Master Mix in optically clear 96-well plates, in a final volume of 25 µl, containing 20 ng DNA. The cycling conditions were according to the manufacturer's instructions.

Table 2Single nucleotide polymorphism genetic data and TaqMan commercial probes used in genotypingGene informationGeneSNPLocationPositionAllelesProbesCD55rs2564978Chr.1:207,321,071IntronC/TACAATGTTCACTCCCTACTGTGTTA[\[C]{.ul}/[T\]]{.ul}TCAACCTGTTTCCCCAGGTCTCTGC1QBPrs3786054Chr.17:5,435,739IntronA/GCTGGCAGGCACCATTCCACACAAGA[\[A]{.ul}/[G\]]{.ul}TACATGAAGGCTGGGCGCAGTGGFCGR2Ars1801274Chr.1:161,509,955IntergenicA/GAATGGAAAATCCCAGAAATTCTCCC[\[A]{.ul}/[G\]]{.ul}TTTGGATCCCACCTTCTCCATCCC*SNP* Single nucleotide polymorphism, *CD55* complement regulatory protein CD55, *C1QBP* complement component 1, *q* subcomponent binding protein, *FCGR2A* Fc fragment of IgG, low affinity IIa, receptor (CD32)

Statistical analysis {#Sec5}
--------------------

Genotype and allele frequencies for the three SNPs were calculated by direct counting. Statistical analysis of the data was performed with SPSS 23.0 software (Chicago, Illinois, USA) using Fisher exact test. All SNPs were tested for Hardy--Weinberg equilibrium (HWE) using Exact test by PLINK software both in mild and severe cases. To investigate all genetic models of association, odds ratios (ORs) and their corresponding 95% confidence intervals (95% CI) were calculated according to dominant (heterozygotes plus minor allele homozygotes vs major allele homozygotes), co-dominant (heterozygotes vs minor allele homozygotes plus major allele homozygotes) and recessive (minor allele homozygotes vs major allele homozygotes plus heterozygotes) model using logistic regression analysis in SPSS 23.0. Additionally, the ORs and their corresponding 95% CIs under the homozygous, heterozygous and allelic models were calculated with logistic regression model using the glm function in R. Moreover, Tukey's Honest Significant Difference (HSD) for post-hoc test was used to fix type I errors through the glht function of multcomp package \[[@CR37]\]. *P* value \< 0.05 was considered statistically significant for all analyses.

Results {#Sec6}
=======

Clinical and demographic features {#Sec7}
---------------------------------

Of the 810 positive for A(H1N1)pdm09 influenza samples in period 2010--11, 110 were selected according to their clinical and demographic features and classified as mild (control = 51) or severe cases (*n* = 59) that had radiographic signs of pneumonia. The average days between the onset of the symptoms and the presentation to the healthcare unit (sample collection) was 4 days. The design of the study and the criteria used for sample selection are described under "Methods" in section "Patient samples". Male sex predominated in both groups (60.8% and 59.3%, respectively), while the mean age of the groups was 37.3 and 36.7 years of age, respectively (Table [1](#Tab1){ref-type="table"}). Of interest, a very low vaccination rate (6.4% of all patients) was noticed in both groups and especially in severe cases, where only 3.4% were vaccinated for seasonal or pandemic influenza. As expected, the majority of fatal cases (85%) in the study had severe clinical signs of influenza infection and differed significantly from the control cases (*P* = 0.005). None of the study participants had any reported comorbidities or other influenza risk factors such as older age (\> 65), pregnancy or obesity.

Distribution of the genotype and allele frequencies {#Sec8}
---------------------------------------------------

Genotype and allele frequencies of CD55 (rs2564978), C1QBP (rs3786054) and FCGR2A (rs1801274) genes are presented in Table [3](#Tab3){ref-type="table"}. Genotype distributions of all three SNPs were consistent with Hardy--Weinberg equilibrium in studied groups (*P* \> 0.05) and their minor allelic frequencies (MAFs) were in accordance to those reported for European populations in the 1000 Genomes project data source (<http://www.1000genomes.org>). As shown in Table [3](#Tab3){ref-type="table"}, there was no significant difference in genotype or allele frequencies of any polymorphism studied between mild and severe cases of influenza. On the contrary, when the distribution of genotype and allele frequencies in association with the mortality was investigated, there was a significant representation of the recessive genotype TT of CD55 rs2564978 (fatality rate 15.8%, *P* = 0.030) in the fatal cases against the non-fatal cases (2.2%). In addition, the percentage of the minor allele T of CD55 rs2564978 was also significantly increased in fatal cases (36.8%, *P* = 0.035) as compared to the non-fatal cases (20.3%) (Table [3](#Tab3){ref-type="table"}). Similarly, patients bearing the recessive genotype AA (fatal cases 10.5% versus non-fatal cases 3.3%) as well as the heterozygous AG genotype (fatal cases 57.9% versus non-fatal cases 37.4%) of C1QBP rs3786054 were significantly increased (*P* = 0.042) in the fatal cases affecting also the frequency of the minor allele A (fatal cases 39.5% versus non-fatal cases 22%, *P* = 0.038) (Table [3](#Tab3){ref-type="table"}). Regarding the FCGR2A rs1801274 polymorphism, although the frequency of the minor allele homozygotes GG increased, there was no genetic variation between the two groups analyzed (Table [3](#Tab3){ref-type="table"}).

Table 3Genotype and allele frequencies of the CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 gene polymorphisms by disease severity (pneumonia) or outcome (death) in patients infected with influenza A(H1N1)pdm09Disease severityFatal outcomeGeneSNP1000 genomes projectTotal*P* ~hwe~MildSevere*P* valueNoYes*P* valueCD55rs2564978Genotype distribution CC*56.164 (58.2)*0.69*33 (64.7)31 (52.5)*0.306*56 (61.5)8 (42.1)*0.030\* CT*37.041 (37.3)17 (33.3)24 (40.7)33 (36.3)8 (42.1)* TT*7.05 (4.5)1 (2.0)4 (6.8)2 (2.2)3 (15.8)*Allele distribution C*74.6169 (76.8)83 (81.4)86 (72.9)*0.152*145 (79.7)24 (63.2)*0.035\* [T]{.ul}*25.451 (23.2)19 (18.6)32 (27.1)37 (20.3)14 (36.8)*C1QBPrs3786054Genotype distribution GG*58.360 (54.5)*0.38*26 (51.0)34 (57.6)*0.331*54 (59.3)6 (31.6)*0.042\* AG*35.445 (40.9)24 (47.0)21 (35.6)34 (37.4)11 (57.9)* AA*6.45 (4.6)1 (2.0)4 (6.8)*3 (3.3)*2 (10.5)*Allele distribution G*75.9165 (75.0)76 (74.5)89 (75.4)*0.877*142 (78.0)23 (60.5)*0.038\* [A]{.ul}*24.155 (25.0)26 (25.5)29 (24.6)40 (22.0)15 (39.5)*FCGR2Ars1801274Genotype distribution AA*25.638 (34.5)*0.77*19 (37.3)19 (32.2)*0.793*34 (37.4)4 (21.1)*0.353 AG*46.552 (47.3)24 (47.0)28 (47.5)42 (46.2)10 (52.6)* GG*27.820 (18.2)8 (15.7)12 (20.3)15 (16.5)5 (26.3)*Allele distribution A*48.9128 (58.2)62 (60.8)66 (55.9)*0.495*110 (60.4)18 (47.4)*0.151 [G]{.ul}*51.192 (41.8)40 (39.2)52 (44.1)72 (39.6)20 (52.6)*1000 Genomes Project Phase 3 genotype and allele frequencies percentages in European population are shown in italics. Minor Allele in each polymorphism is underlined. Genotypes and alleles are presented as number of patients and their percentage distribution in italics *(%)*. P~hwe~: probability of adherence to the Hardy--Weinberg equilibrium (HWE) expectations\**P* \< 0.05

No significant differences in risk association of the three SNPs investigated were observed when patients with mild and severe influenza symptoms were compared under the dominant, co-dominant and recessive genetic models as shown in Table [4](#Tab4){ref-type="table"}. Moreover, there were no differences observed even when the dominant genotype of each SNP was compared with its corresponding recessive genotype. Similarly, allelic odds ratios of CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 revealed no differences in risk associated with influenza severity. The same analysis was carried out to uncover the genetic association between the three SNPs studied and the mortality risk. Indeed, minor allele homozygote patients of the CD55 rs2564978 presented 8.3 times increased risk (*P* = 0.026, OR 8.344, 95% CI 1.290--53.957) in fatal outcome than the major allele homozygotes plus heterozygotes under the recessive genetic model. The risk was further increased to 10.5-fold (*P* = 0.043, OR 10.500, 95% CI 1.062--103.788) when comparing the difference in odds between minor allele homozygotes vs major allele homozygotes. Additionally, under the allelic model of comparison, the patients carrying the T allele presented about 2.3 times increased risk (*P* = 0.031, OR 0.437, 95% CI 0.206--0.927) in fatal outcome compared to the patients with the C allele. Regarding C1QBP rs3786054, when comparing the major allele homozygotes GG with the minor allele homozygotes AA and heterozygotes AG under the dominant genetic model, the latter were found significantly associated with increased risk of mortality by threefold (*P* = 0.032, OR 3.162, 95% CI 1.102--9.072). This finding was further supported by the significant increase in odds of dying if harboring the minor allele A than the major allele G (*P* = 0.026, OR 0.432, 95% CI 0.206--0.904). In contrast, there was no significant difference in odds regarding the FCGR2A rs1801274 polymorphism under any genetic model examined. The results of association analysis under the seven different genetic models are summarized in Table [4](#Tab4){ref-type="table"}.

Table 4Estimated effect of association of the CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 gene polymorphisms by disease severity (pneumonia) or outcome (death) in patients infected with influenza A(H1N1)pdm09Disease severityFatal outcomeGeneSNPGenetic modelOR95% CI*P* valueOR95% CI*P* valueCD55rs2564978Dominant: CT + TT vs CC1.6560.768--3.5720.1982.2000.806--6.0030.124Co-dominant: CT vs CC + TT1.3710.629--2.9920.4281.2780.467--3.4960.632Recessive: TT vs CT + CC3.6360.393--33.6330.2558.3441.290--53.9570.026\*Heterozygote: CT vs CC1.6500.645--4.2210.4181.6970.478--6.0190.587Homozygote: TT vs CC4.4000.318--60.9260.37810.5001.062--103.7880.043\*Heterozygote: TT vs CT2.6670.185--38.4410.6596.1870.617--62.0580.151Allelic: C vs T0.6150.323--1.1700.1390.4370.206--0.9270.031\*C1QBPrs3786054Dominant: AG + AA vs GG0.7650.360--1.6250.4853.1621.102--9.0720.032\*Co-dominant: AG vs AA + GG0.6220.289--1.3370.2242.3050.844--6.2970.103Recessive: AA vs AG + GG3.6360.393--33.6330.2553.4510.536--22.2350.193Heterozygote: AG vs GG0.6650.265--1.6690.5462.9120.807--10.4990.123Homozygote: AA vs GG3.0580.220--42.4330.5746.0000.577--62.3950.170Heterozygote: AA vs AG4.6000.323--65.4550.3642.0600.214--19.8650.732Allelic: G vs A1.0500.567--1.9360.8760.4320.206--0.9040.026\*FCGR2Ars1801274Dominant: AG + GG vs AA1.2500.569--2.7480.5792.2370.686--7.2930.182Co-dominant: AG vs AA + GG1.0160.480--2.1530.9671.2960.481--3.4900.608Recessive: GG vs AG + AA1.3720.512--3.6770.5291.8100.566--5.7820.317Heterozygote: AG vs AA1.0660.388--2.9290.9882.0240.458--8.9450.505Homozygote: GG vs AA1.4210.381--5.2960.8052.8330.503--15.9720.334Heterozygote: GG vs AG1.3330.381--4.6670.8521.4000.324--6.0430.851Allelic: A vs G0.8190.478--1.4030.4670.5870.292--1.1890.140*OR* odds ratio, *95% CI* 95% confidence interval^\*^*P* \< 0.05

Discussion {#Sec9}
==========

The emergence of the recent influenza pandemic in 2009 led more than 18,000 people (mostly young adults) to death worldwide \[[@CR38]\]. In Greece, during the pandemic and the post-pandemic season, 329 people died, with the highest mortality rate being between 46 and 64 years of age \[[@CR4], [@CR5]\]. Indeed, in our study, the mean age of fatal cases was 48.21 years, while the mean ages of mild and severe cases with fatal outcome were 52.67 and 47.37 years, respectively. Another important issue to be highlighted is the very low vaccination rate in general population, although the influenza vaccination was offered for free in Greece. The vaccination coverage of our study population, which does not include high-risk groups, was 6.4%, a relatively low rate, but in accordance with the general population which was 5.9% that year \[[@CR5]\]. Scientific and national health policies need to be applied, since low vaccination coverage may lead to epidemics, as it was observed in the recent measles epidemic in Europe.

The increased mortality rate in young adults triggered the present study to reveal the potential role of host genetics in the severity of illness as demonstrated by the presence of pneumonia or the fatal outcome. Towards that goal we decided to investigate the association between the innate-immunity-related gene SNPs of CD55 rs2564978, C1QBP rs3786054 and FCGR2A rs1801274 and the severity of pandemic A(H1N1)pdm09 influenza in a European population. It is interesting to note that amongst these three SNPs only in the first two of them we were able to obtain statistically significant data, as discussed below.

CD55 is a membrane-associated protein that regulates complement activation by interfering with C3/C5 convertases both in classical and alternative pathway, and naturally protects host cells from damage of pathogens. The TT genotype of rs2564978, that results in reduced promoter activity \[[@CR29]\], is relatively rare in Europe (7%) according to the 1000 Genomes project data source and was found in only 4.5% of our overall patients (Table [3](#Tab3){ref-type="table"}). However, there was a significant overrepresentation of the TT genotype in fatal cases that reached 15.8% (*P* = 0.030), and only 2.2% in survivors. Similar observation was seen by comparing the minor allele T distribution, since it was 36.8% in fatal cases vs 20.3% in non-fatal cases of our patient group. The resulted reduced expression of CD55 in patients carrying the rare TT genotype may lead to more robust complement activation during infection, resulting in worse outcomes secondary to enhanced inflammation \[[@CR23]\]. Similarly, the death risk association was found significantly increased by more than eightfold in fatal cases (*P* = 0.026, OR 8.344, 95% CI 1.290--53.957), a result that is rather overestimated because of the small sample size in our study. Consistent with our findings, a recent study in Spain indirectly associated rs2564978 with influenza severity (*P* = 0.0064, OR 7.11, 95% CI 1.400--36.00) \[[@CR39]\]. These findings are in accordance with those of Zhou and colleagues \[[@CR29]\] that first described the significant association of the TT genotype with severe influenza infection (*P* = 0.011, OR 1.75, 95% CI 1.13--2.70) in Chinese patients based on a small-scale genome-wide association study (GWAS). Recently, a second study from China did not find any significant association between rs2564978 and the primary outcome in cases of avian (H7N9) or pandemic influenza, but TT genotype was linked to severity \[[@CR40]\]. The fact that the TT genotype in East Asian populations is much more prevalent than in the rest of the world (35% vs 7%) according to the 1000 Genomes project data source, underlies the importance of this polymorphism in influenza severity and further attention is needed. Our study is the first presenting a positive correlation between fatal outcome and the TT genotype and this finding needs to be confirmed in a bigger cohort.

Apart from CD55, the study also focused on the association of host genetic polymorphisms with influenza severity of another protein related to complement cascade, since its role in viral defense is well established. The C1QBP gene encodes for a protein that binds to C1q molecule, a component known as an important regulator of antiviral antibody effector mechanisms of the classical pathway of complement activation, and thus inhibiting C1 \[[@CR41]\]. C1QBP rs3786054 was one of the four SNPs (together with FCGR2A rs1801274, an unknown gene rs9856661 and RPAIN rs8070740) identified as significant risk factors on the severity of influenza infection in a case--control genetic association study in Mexican population. A threefold increase in risk of severe disease (*P* \< 0.0001, OR 3.13, 95% CI 1.89--5.17) was found for patients homozygous for the minor allele \[[@CR22]\]. Although we did not find any significant association of the rare AA genotype with severity in any genetic model studied, we found a threefold increased risk of death in dominant genetic model for the major G-allele (*P* = 0.032, OR 3.162, 95% CI 1.102--9.072). Moreover, the frequency of the rare AA genotype was significantly increased from 4.6% in all patients to 10.5% in patients who died. Additionally, the allele distribution of the minor allele A was also significantly (*P* = 0.038) increased in fatal cases (39.5%) as compared to non-fatal cases (22%). Unlikely, the association of rs3786054 with influenza severity could not be replicated in a recent GWAS \[[@CR39]\] and thus in view of the contradictory results observed in different disease association studies, further research is required to clarify the role of this genetic polymorphism.

Another polymorphism, namely the rs1801274 on FCGR2A gene, was reported as candidate risk association factor in a study from Mexico \[[@CR22]\]. The nonsynonymous A/G polymorphism rs1801274 causes an amino acid substitution at position 131 (His131Arg), which is known to affect the affinity of the FCGR2A for different subtypes of IgG \[[@CR42]\]. The effector cells of AA homozygous individuals bind stronger to IgG2 resulting to more effective antigen clearance \[[@CR43]\]. The enhanced host immune response might be the cause of severe disease outcome of A(H1N1)pdm09 influenza infection, taking into account that protein encoded by FCGR2A participates in the clearing of immune complexes \[[@CR22], [@CR23]\]. Zuniga and colleagues reported a significant increase of minor allele frequency in severe cases compared with control group (36% and 13%, respectively) as well as increased risk of association (*P* \< 0.0001, OR 2.68, 95% CI 1.69--4.25) with severity. However, these results do not concur with our findings regarding either the presence of pneumonia or the risk of mortality where no association was established under any genetic model tested. In accordance with our findings, a recent study from Brazil failed to reveal any differences in allele or genotype frequencies of the rs1801274 polymorphism and its association with influenza disease severity or death (*P* \> 0.05) \[[@CR44]\]. Moreover, the association of rs1801274 with influenza severity was not even indirectly replicated in a European GWAS where more than half a million SNPs were investigated \[[@CR39]\]. Probably the false discovery rate of 36% for rs1801274 in the study of Zuniga and colleagues, \[[@CR22]\] because of the small size of the study, misled them to positive results. The main drawbacks of current studies is either the small sample size and/or the inability of generating compared groups for age, sex, ethnicity without confounding underlying medical conditions that question the importance of the findings and the overall polymorphism implication.

In this study, samples were collected during the short outbreak of A(H1N1)pdm09 influenza in the post pandemic period 2010--11. To eliminate ethnicity stratification that is an important confounding factor in genetic association studies, only Greek ethnicity patients were enrolled. Further, our study is restricted to patients without previous known influenza comorbidities, and cases were diagnosed with pneumonia. Such study design led to the inclusion of only 110 cases for further genotyping out of 810 cases examined. Our results show that two independent complement-related SNPs, namely the rare TT genotype of CD55 as well as the rare AA genotype of C1QBP are associated with increased death risk, but not with the disease severity based on the stratification sample criteria applied. No significant differences were observed for FCGR2A genotypes. Genotype distributions of all three SNPs investigated were consistent with Hardy--Weinberg equilibrium and their MAFs were in accordance to those reported for European populations in the 1000 Genomes project data source. Since all patients in our study had no other risk factors, our findings could lead to the identification of population groups at genetic risk. Additional genetic association studies could support our findings to the identification of new at-risk populations to whom the implementation of vaccination will help prevent influenza infection and its implications. Furthermore, their early recognition will reduce the financial burden due to less hospitalization.
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